Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Jul 20, 2017
Durable CRs Continued After Recovery of Normal B Cells Anti-CD19 CAR T-cell Therapy Can Be Curative for Chemorefractory Aggressive NHL SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE), a leading cell therapy company, highlight...
Jun 28, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc., (Nasdaq:KITE), a leading cell therapy company, today announced that the United States Patent and Trademark Office (USPTO) has provided a Notice of Intent to issue an Ex Parte Reexamination Certificate that confirms the patentability of amended claims pres...
Jun 27, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc., (Nasdaq:KITE), a leading cell therapy company, has been named to MIT Technology Review's 2017 list of 50 Smartest Companies. To make the list, a company must exhibit technological leadership and business acumen which sets them apart from competitors. ...
Jun 6, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc., (Nasdaq:KITE), a leading cell therapy company, today announced that management will present at two investor conferences in June 2017: Jefferies 2017 Global Healthcare ConferenceWednesday, June 71:30pm Eastern TimeNew...
Jun 5, 2017
Remissions Ongoing From 2.0 to Greater than 7.4 Months KTE-C19 Successfully Manufactured in Six Days Across a Range of Absolute Lymphocyte and Blast Counts Phase 2 Initiation Planned for 2017 SANTA MONICA, Calif.--(BUSINESS WIRE)-- ...
May 26, 2017
First Investigational CAR-T Therapy to Demonstrate Positive Data in Aggressive Non-Hodgkin Lymphoma (NHL) Biologics License Application Submission Based on the Primary Analysis of the ZUMA-1 Phase 2 Trial Prescription Drug User Fee Act (PDUFA) Set for November 29, 2...
May 17, 2017
Clinical and Biomarker Correlates of Outcomes in ZUMA-1 Pivotal Trial of axicabtagene ciloleucel in Refractory, Aggressive Non-Hodgkin Lymphoma (NHL) Updated Efficacy and Safety Data from ZUMA-3, a Phase 1/2 study of KTE-C19 in Adult Patients with Relapsed/Refractory Acute Lymphoblasti...
May 8, 2017
Completed Submission of Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Kite's CAR-T Therapy, Axicabtagene Ciloleucel, in Patients with Aggressive Non-Hodgkin Lymphoma (NHL) Initiated Two New Clinical Studies as Part of an Expanded KTE-C19 ...
May 1, 2017
Conference Call and Webcast Scheduled for 8:30 AM ET / 5:30 AM PT SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc., (Nasdaq:KITE) today announced that it will report first quarter 2017 financial results on Monday, May 8, 2017 prior to the open of U.S. based financial markets. The an...
Apr 6, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc., (Nasdaq:KITE) today announced that it won the Clinical Trial Result of the Year award for ZUMA-1, its pivotal CAR-T trial of axicabtagene ciloleucel, in patients with refractory aggressive B-cell non-Hodgkin lymphoma (NHL) at the Clinical and Research ...
Apr 4, 2017
Proprietary Linker and CD28 Costimulatory Domain for Polyfunctional T cell Activation without Tonic Signaling Phase 1 Clinical Study of KITE-585 in Patients with Multiple Myeloma Planned for 2017 SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma...
Apr 4, 2017
Proprietary Serum-Free Artificial Thymic Organoid (ATO) Reproduces T-Cell Differentiation in Human Thymus System Offers Technical Simplicity, Reproducibility, and Potential Scalability Kite Holds Exclusive License to the ATO Technology for the Development ...
Apr 2, 2017
44 Percent in Ongoing Response, Including 39 Percent in Complete Response (CR) with a Median Follow-up of 8.7 Months Median Duration of Response for CR Not Yet Reached Second Plenary Presentation Identified Biomarkers Associated with Response and Adverse Events ...
Mar 31, 2017
Kite is Preparing for Potential Approval and Launch for Axicabtagene Ciloleucel in 2017 SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced that it has completed the rolling submission with the U.S. Food and Drug Administration (FDA) o...
Mar 30, 2017
Plenary Presentation on Positive Primary Analysis of the ZUMA-1 Pivotal CAR-T Trial in Patients with Aggressive Non-Hodgkin Lymphoma Plenary and Oral Presentations Highlighting Biomarkers and Product Characteristics Associated with Adverse Events and Objective Response in Patients with...
Mar 16, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced that Owen N. Witte, M.D., the founding director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at the University of California Los Angeles (UCLA) and a renowned cancer researcher, h...
Mar 14, 2017
50 Percent of Patients in Ongoing Complete Remission with Duration Ranging from 7+ to 24+ months Study Demonstrates that IL-15 Blood Levels and CAR T-Cell Expansion Correlate to an Improved Clinical Outcome Conducted Under a Cooperative Research and Development Agre...
Mar 8, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced the closing of its previously announced underwritten public offering of 4,750,000 shares of its common stock at a price to the public of $75.00 per share, as well as the exercise in full of the underwriters' option to purchase...
Mar 6, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced that management will present at two investor conferences in March 2017: • Cowen 37th Annual Health Care Conference ...
Mar 5, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc., (Nasdaq:KITE) today announced that Richard L. Wang, Ph.D. will be appointed Chief Executive Officer of Fosun Kite Biotechnology Co., Ltd, the company's 50/50 owned joint venture in China with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (60019...
Mar 2, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced the pricing of its previously announced underwritten public offering of 4,750,000 shares of its common stock at a price to the public of $75.00 per share. The offering is expected to close on or about March 7, 2017, subject to...
Mar 2, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq: KITE) today announced the commencement of an underwritten public offering of 4,750,000 shares of its common stock. In addition, Kite has granted the underwriters of the offering a 30-day option to purchase up to an additional 712,500 shares of its...
Feb 28, 2017
Strong Execution Across Clinical Development, Pipeline, Manufacturing and Pre-Commercial Activities in 2016 On Track to Complete Rolling Biologics License Application to the U.S. Food and Drug Administration for Axicabtagene Ciloleucel by End of First Quarter 2017 ...
Feb 28, 2017
Met Primary Endpoint of Objective Response Rate (p...
Feb 27, 2017
Conference Call and Webcast Scheduled for 6:00 AM PT/9:00 AM ET SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced that it will report fourth quarter and full year 2016 financial results on Tuesday, February 28, 2017, prior to the open of the market. The ...
Jan 10, 2017
Kite to Receive Upfront Payment of $40 Million, Milestone Payments, Profit Share and Sales Royalties Upon Commercialization of Axicabtagene Ciloleucel (approved USAN name for KTE-C19) in China Fosun Pharma to Provide $20 Million in Initial Funding to Support Clinical Development and Ma...
Jan 9, 2017
Upfront and Milestone Payments Total $250 Million Plus Double Digit Sales Royalties Accelerates Development of Axicabtagene Ciloleucel for Aggressive Non-Hodgkin Lymphoma (NHL) in Third-Largest Pharmaceutical Market in the World SANTA MONICA, Ca...
Jan 5, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced that Ian T. Clark, former Chief Executive Officer, Head of Commercial Operations and member of the Board of Directors for Genentech Inc., a member of the Roche Group, has been appointed to its Board of Directors. Clar...
Jan 4, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (NASDAQ:KITE) today announced that Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer, will present at the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017 at 4:30 PM Pacific Time. The event wi...
Jan 3, 2017
Directed Against a Validated TCR Target in Solid Tumors Built on the National Cancer Institute Proof of Concept Work and Optimized to Include Next Generation T-cell Manufacturing Technologies SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharm...
Dec 19, 2016
Kite to Appeal USPTO Declining to Revoke Narrow Patent Against Certain CAR-T Constructs having a Single Specified CD28 Sequence Kite Successfully Defeats 3rd Party Challenge to Kite CAR-T Patent which Covers Methods for Using Modified T cells Containing scFv Binding Elements and Other ...
Dec 13, 2016
Strategic Partnership will Connect Vitruvian's Cloud-Based Software with Kite Pharma's Kite Konnect™ Platform to Enable Commercial-Scale Logistics for T-cell Therapies SANTA MONICA, Calif. and SAN FRANCISCO--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq: KITE) and Vitruvian Networks, Inc...
Dec 12, 2016
Publication Describes Work Pertaining to the Cooperative Research and Development Agreement (CRADA) between the National Institutes of Health (NIH) and Kite Pharma Kite Pharma Has an Exclusive License from NIH to Multiple T Cell Receptor (TCR) Product Candidates Targeting Mutant KRAS t...
Dec 6, 2016
76 Percent of Patients with Diffuse Large B-Cell Lymphoma Achieved Objective Response (p ...
Dec 4, 2016
•First CAR-T Therapy BLA Filing Initiated with the U.S. Food and Drug Administration •Company Expects to Complete BLA Submission by the end of Q1 2017 •United States Adopted Name, or USAN, for KTE-C19 will be axicabtagene ciloleucel ...
Dec 4, 2016
• 100 Percent of Responders Tested Negative for Minimal Residual Disease (MRD) SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced that 82 percent of patients (9 out of 11) achieved complete remission or complete remission wi...
Dec 1, 2016
Company Strengthens Supply Chain Operations as it Prepares for Potential Approval and Launch of KTE-C19 for Aggressive non-Hodgkin Lymphoma by the U.S. Food and Drug Administration in 2017 SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq: KITE) today a...
Nov 21, 2016
KTE-C19 Significantly Improved Objective Response Rate in Patients with Chemorefractory DLBCL at Pre-Defined Interim Analysis Represents One of Only Six Abstracts Accepted as a Late-Breaking Presentation SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kit...
Nov 9, 2016
Company Announces Plans to Initiate a Rolling Submission of the Biologics License Application for KTE-C19 with the U.S. Food and Drug Administration for an Expanded Indication of Aggressive Non-Hodgkin Lymphoma in December 2016 with a Targeted Completion in Q1 2017 Potential Approval a...
Nov 3, 2016
Oral Presentation on Novel T cell Manufacturing Process for KTE-C19 in Acute Lymphoblastic Leukemia (ALL) Poster Presentation of Preliminary Safety and Efficacy Data from the Phase 1 Portion of ZUMA-3 and ZUMA-4 Trials in Adult and Pediatric Patients with Relapsed/Refractory (R/R) ALL ...
Nov 2, 2016
Conference Call and Webcast Scheduled for 8:30 AM PT/11:30 AM ET SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced that it will report third quarter 2016 financial results on Wednesday, November 9, 2016, prior to the open of the market. The announcement ...
Oct 28, 2016
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced that management will present at three investor conferences in November: • Credit Suisse 25th Annual Healthcare Conference Date: Monday, November 7, 2016 ...
Oct 19, 2016
Four New Clinical Programs Unveiled to Drive Long-Term Growth T cells 2.0 Next Generation Programming to Realize Full Potential of Cell Therapy KTE-C19 Expansion Studies with the Potential to Deliver Six Additional Indications in B-cell Malignancies ...
Oct 13, 2016
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced the appointment of Chris Nowers as its Head of Europe. Nowers will be based in London. In his new role, Nowers will oversee European commercial operations to build awareness in the region of Kite's growing pipeline portfolio o...
Oct 11, 2016
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced that it will hold an Investor Day on October 18, 2016 in New York where the company will share updates on its advancing pipeline of chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates, next generation ...
Oct 7, 2016
43 Percent Complete Remission Rate Continues at 12-Month Follow-Up SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced updated results from the Phase 1 portion of Kite's ZUMA-1 clinical trial of its lead product candidate, KTE-C19, in patients with chemore...
Oct 6, 2016
First patient enrolled in ZUMA-6 study evaluating safety and efficacy of anti-CD19 CAR (KTE-C19) therapy in combination with anti-PD-L1 monoclonal antibody atezolizumab SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced the first patient was enro...
Sep 29, 2016
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) has announced the appointment of Christine Cassiano as Senior Vice President of Corporate Communications and Investor Relations. She will also sit on the company's Executive Committee. In this new position, Cassiano will be responsible for ...
Sep 26, 2016
Study Met Primary Endpoint of Objective Response Rate (p...
Sep 20, 2016
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T-cell therapy (eACT™) products for the treatment of cancer, today announced that the Company has entered into an exclusive, worldwide license with ...
Aug 31, 2016
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc., (Nasdaq:KITE) today announced that management will participate in a panel at the 11th Annual Citi Biotech Conference and a fireside chat discussion at the Morgan Stanley Global Healthcare Conference. ...
Aug 19, 2016
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced that two of its key advisors and scientific collaborators, both pioneers in the field of cancer immunotherapy, have received the renowned Novartis Prize for Clinical Immunology. The winners were select...
Aug 8, 2016
Interim Results from Pivotal Phase 2 Portion of ZUMA-1 Clinical Trial of KTE-C19 Expected in Late Third Quarter of 2016 KTE-C19 Biologics License Application Filing Planned in Late 2016; Commercial Launch of KTE-C19 Expected in 2017 Kite Investor Day Scheduled for October 18, 2016 ...
Aug 3, 2016
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc., (Nasdaq:KITE) today announced that management will present at the Canaccord Genuity 36th Annual Growth Conference. Event: Canaccord Genuity 36th Annual Growth ConferenceDate: Wednesday, August 10, 2016Time: 2:00 PM Eastern TimeLoc...
Aug 1, 2016
Conference Call and Webcast Scheduled for 4:30 PM Eastern Time SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced that it will report second quarter 2016 financial results on Monday, August 8, 2016, after market close. The announcement will be followed by...
Jul 27, 2016
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T-cell therapy (eACT™) products for the treatment of cancer, today announced that the Company has entered into an exclusive, worldwide license with ...
Jul 25, 2016
Platform for Renewable T-Cell Source Designed to Overcome Limitations of Current Allogeneic Approaches SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T-cell therapy (eACT...
Jul 7, 2016
Interim Efficacy Results and BLA Filing Expected in 2016 SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq: KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous cell therapy (eACT™) products for the treatment of cancer, announced...
Jun 20, 2016
43,500-Square-Foot Plant Next to Los Angeles International Airport Will Support Production of Engineered CAR and TCR Cancer Immunotherapies Preparations on Track to Launch Lead Product Candidate KTE-C19 in 2017 SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq...
Jun 20, 2016
New CRADA with the NCI's Experimental Transplantation and Immunology Branch Accelerates Development of HPV-16 E7 TCR Product Candidate SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (NASDAQ:KITE) today announced that it has entered into a new Cooperative Research and Development A...
Jun 8, 2016
Results from ZUMA-1 Phase 1 study of KTE-C19 in patients with chemorefractory diffuse large B-cell lymphoma (DLBCL) SCHOLAR-1, first meta-analysis of patient-level outcomes in chemorefractory DLBCL, an understudied patient population Results from study of anti-CD19 CAR T cells in a...
Jun 6, 2016
9 of 19 patients (47%) with diffuse large B-cell lymphoma achieved complete responses, which are all ongoing with a duration of 7 to 20 months CHICAGO--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) ("Kite") today announced results to be presented at the 2016 American Society of ...
Jun 6, 2016
Median overall survival was 6.6 months and consistent across subgroups including refractory status, stage of disease and line of therapy Overall response rate was 26% with only 8% achieving a complete response Data provide a benchmark for future studies ...
Jun 6, 2016
CHICAGO--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) ("Kite") today announced updated durability of complete responses in the Phase 1 portion of the ZUMA-1 trial. The study is evaluating KTE-C19 in patients with chemorefractory diffuse large B-cell lymphoma (DLBCL), an aggressive form of non-Hodgkin ...
Jun 2, 2016
Kite to License Cell Design Labs' Synthetic Biology Technology for Applications in Acute Myeloid Leukemia with Exclusive Option for Applications in B-cell Malignancies Cell Design Labs' Reversible ‘On/Off Switch' Technology Provides Dynamic Range of Control to Precisely Regulate ...
Jun 1, 2016
PRIME, A New European Medicines Agency Initiative, Provides Enhanced Scientific Guidance and Supports Accelerated Review of Investigational Therapies Addressing Unmet Medical Need KTE-C19 Included in the First Cohort of Investigational Therapies to Qualify for PRIME Initiative ...
May 31, 2016
SCHOLAR-1, a retrospective meta-analysis of patient outcomes from two observational databases and two Phase 3 studies, highlights unmet medical need in chemorefractory diffuse large B-cell lymphoma Study of anti-CD19 chimeric antigen receptor (CAR) T cells in advanced lymphoma patients, conducted ...
May 27, 2016
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced that management will present at two investor conferences in June: Jefferies 2016 Healthcare Conference Date: Tuesday, June 7, 2016 Time: 11:00 AM EDT ...
May 16, 2016
Led Worldwide Commercial and Corporate Financial Planning Functions at Allergan SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq: KITE) today announced the appointment of Paul L. Jenkinson as Chief Financial Officer, reporting to Arie Belldegrun, M.D., FACS, Kite's ...
May 9, 2016
Durable Treatment Effect of KTE-C19 Supported by Updated Patient Follow-up in ZUMA-1 Trial Presented at Annual Meeting of the American Association of Cancer Research (AACR) Interim Results from Pivotal Phase 2 Portion of KTE-C19 ZUMA-1 Trial Expected in Second Half of 2016, to Support Planned BLA ...
May 3, 2016
Conference Call and Webcast Scheduled for 4:30 PM Eastern Time SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc., (Nasdaq:KITE) today announced that it will report first quarter 2016 financial results on Monday, May 9, 2016 after market close. The announcement will be followed by a l...
May 2, 2016
All Hematological Malignancies Targeted by KTE-C19 Development Now Covered by Orphan Drug Designations in U.S. and EU SANTA MONICA, Calif., May 02, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) ("Kite"), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products fo...
Apr 28, 2016
SANTA MONICA, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE) ("Kite") a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced four presentations to be delivered at the upcoming American Society of Gene & C...
Apr 19, 2016
SANTA MONICA, Calif., April 19, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) ("Kite") today announced updated clinical results from the phase 1 portion of Kite's ZUMA-1 trial of its lead product candidate, KTE-C19, in patients with chemorefractory, aggressive non-Hodgkin lymphoma (NHL). KTE-C19 is an investigational therapy in which a...
Apr 18, 2016
Antoni Ribas, M.D., Ph.D. and Ronald Levy, M.D. recognized for their major contributions to cancer research SANTA MONICA, Calif., April 18, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), today announced that two members of its Scientific Advisory Board (SAB) are being honored at this year's annual meeting of the AACR.  Antoni Ri...
Apr 16, 2016
- Kite's four ongoing multi-center clinical trials of its lead product candidate, KTE-C19, are continuing - - Kite remains on track to file an investigational new drug application (IND) with the Food and Drug Administration (FDA) by the end of this year for a T cell receptor (TCR)-based product candidate targeting a MAGE antigen for the treatm...
Apr 15, 2016
SANTA MONICA, Calif., April 15, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE) ("Kite") a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced the schedule of presentations and addresses related to its engineered cell ther...
Mar 17, 2016
SANTA MONICA, Calif., March 17, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced that it has entered into a clinical trial collaboration with Genentech, a member of the Roche Group, to evaluate the safety and efficacy of KTE-C19, in combination with atezolizumab (also known as MPDL3280A), in patients with refractory, aggre...
Mar 16, 2016
SANTA MONICA, Calif., March 16, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE) ("Kite") a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced two oral presentations and two poster presentations to be delivered at the upco...
Mar 16, 2016
SANTA MONICA, Calif., March 16, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced the appointment of Tim Moore as Executive Vice President, Technical Operations. With more than three decades of industry experience, Mr. Moore will be responsible for product development, manufacturing, supply chain, quality assurance, and end...
Mar 3, 2016
SANTA MONICA, Calif., March 03, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE) today announced that management will present at two investor conferences in March: Cowen and Company 36th Annual Health Care ConferenceDate:  Tuesday, March 8, 2016Time: 10:40AM Eastern TimeLocation:  Boston, MABarclays Global Healthcare ConferenceDate:  ...
Feb 29, 2016
- Interim KTE-C19 Data, Expected in Second Half of 2016, to Support Planned BLA Filing in Late 2016 and Potential Product Launch in 2017 -             - Balance Sheet Further Strengthened Through 2015 Public Offering, $614.7 Million in Cash and Investments - SANTA MONICA, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:K...
Feb 24, 2016
SANTA MONICA, Calif., Feb. 24, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous cell therapy (eACT™) products for the treatment of cancer, today announced the formation of the company's integrated commercial leadership team with the appointment o...
Feb 24, 2016
SANTA MONICA, Calif., Feb. 24, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE) today announced that it will report fourth quarter and full year 2015 financial results on Monday, February 29, 2016 after market close, and will host a conference call to discuss financial results and provide a business update at 4:30 PM Eastern Time (1:30 P...
Feb 16, 2016
SANTA MONICA, Calif., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE) today announced that David D. Chang, M.D., Ph.D., Executive Vice President, Research and Development, and Chief Medical Officer, will participate in a fireside chat discussion at the 2016 RBC Capital Markets Global Healthcare Conference. Event: 2016 RBC C...
Jan 13, 2016
SANTA MONICA, Calif., Jan. 13, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced that its European subsidiary has entered into a research and license agreement with Leiden University Medical Center (LUMC) to identify and develop T cell receptor (TCR) product candidates targeting solid tumors that are associated with the hum...
Jan 7, 2016
SANTA MONICA, Calif., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (NASDAQ:KITE) today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the NCI for the research and clinical development of a fully human anti-CD19 chimeric antigen receptor (CAR) product candidate for the trea...
Jan 6, 2016
SANTA MONICA, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (NASDAQ:KITE) today announced that Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer, will present at the 34th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2016 at 8:30 AM Pacific Time.  The event will be held in San Francisco...
Dec 21, 2015
SANTA MONICA, Calif., Dec. 21, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (NASDAQ:KITE) today announced that it has appointed Shawn Tomasello to the newly created position of Chief Commercial Officer. With over 30 years of experience in the life sciences industry, Ms. Tomasello has led commercial and medical affairs efforts at P...
Dec 11, 2015
SANTA MONICA, Calif., Dec. 11, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced that the underwriters of its previously announced underwritten public offering have exercised in full their option to purchase an additional 543,750 shares of Kite's common stock. Including this option exercise, total gross proceeds to Kite from ...
Dec 10, 2015
SANTA MONICA, Calif., Dec. 10, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced the pricing of an underwritten public offering of 3,625,000 shares of its common stock at a price to the public of $69.00 per share. The gross proceeds to Kite from the offering, before deducting the underwriting discounts and commissions and oth...
Dec 8, 2015
SANTA MONICA, Calif., Dec. 8, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced that it has commenced an underwritten public offering of approximately $250 million of shares of its common stock. Kite expects to grant the underwriters of the offering a 30-day option to purchase up to an additional $37.5 million of shares of it...
Dec 7, 2015
SANTA MONICA, Calif., Dec. 7, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced clinical biomarker data and product characteristics for anti-CD19 chimeric antigen receptor (CAR) T cell therapy in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) enrolled in an ongoing phase 1-2 clinical trial at the National Cancer...
Dec 7, 2015
SANTA MONICA, Calif., Dec. 7, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced clinical results and biomarker data for the phase 1 portion of Kite's ZUMA-1 trial of KTE-C19 in patients with refractory, aggressive non-Hodgkin lymphoma (NHL). KTE-C19 is an investigational therapy in which a patient's T cells are genetically mo...
Dec 7, 2015
SANTA MONICA, Calif., Dec. 7, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced that it has initiated a phase 1/2 clinical study of KTE-C19 (ZUMA-4) for the treatment of pediatric and young adult patients with r/r ALL. KTE-C19 is an investigational therapy in which a patient's T cells are genetically modified to express a chi...
Dec 7, 2015
SANTA MONICA, Calif., Dec. 7, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation status to the Company's lead product candidate, KTE-C19, for the treatment of patients with refractory diffuse large B cell lymphoma (DLBCL), primary med...
Dec 3, 2015
SANTA MONICA, Calif. and NISKAYUNA, N.Y., Dec. 3, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, and GE Global Research (NYSE:GE), the centralized research and development hub for GE, t...
Dec 2, 2015
SANTA MONICA, Calif., Dec. 2, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous cell therapy (eACT™) products for the treatment of cancer, today announced that it has initiated a phase 1/2 clinical study of KTE-C19 (ZUMA-3) for the treatment of adul...
Nov 12, 2015
SANTA MONICA, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today reported financial results for the quarter ended September 30, 2015. "Over the past few months, w...
Nov 9, 2015
SANTA MONICA, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced that management will host a conference call and live webcast discussion at 4:30 p.m. Eastern Time on Thursday, November 12, 2015, to discuss financial results for the third quarter ended September 30, 2015, and provide a business update. T...
Nov 9, 2015
SANTA MONICA, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that it has initiated a phase 2 clinical study of KTE-C19 (ZUMA-2) for the treatment of r/r ...
Nov 5, 2015
SANTA MONICA, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced upcoming presentations related to KTE-C19, Kite's lead product candidate, that will take place at the 57th ASH Annual Meeting in Orlando, Florida, December 5-8, 2015. KTE-C19 is an investigational therapy in which a patient's T cells are ge...
Nov 4, 2015
SANTA MONICA, Calif., Nov. 4, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced that management will present at several upcoming investor conferences this month:Credit Suisse Healthcare Conference Date: Tuesday, November 10, 2015 Time: 10:30am Mountain Time Location: Phoenix, AZStifel Nicolaus Healthcare Conf...
Nov 2, 2015
SANTA MONICA, Calif., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that it has opened enrollment for the Phase 2 portion of its ongoing Phase 1/2 clinical tria...
Oct 27, 2015
SANTA MONICA, Calif. and SEATTLE, Oct. 27, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced that it has entered into a worldwide research and license agreement with Alpine Immune Sciences, Inc. (AIS), a privately-held biotechnology company, to discover and develop protein-based immunotherapies targeting the immune syn...
Oct 20, 2015
SANTA MONICA, Calif., Oct. 20, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that the Company has entered into an exclusive, worldwide license with the National Institu...
Oct 15, 2015
COMP Opinions Recommend EU Orphan Designation for the Treatment of Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), and Follicular Lymphoma (FL) SANTA MONICA, Calif., Oct. 15, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused...
Oct 7, 2015
SANTA MONICA, Calif., Oct. 7, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced that Steven A. Rosenberg, M.D., Ph.D., Chief of Surgery at the National Cancer Institute (NCI) and a special advisor to Kite, has received three significant awards for his achievements and career dedicated to advancing cancer research. The ...
Oct 1, 2015
- TCR product candidate targeting human papillomavirus (HPV)-16 E6 selectively kills cervical and head and neck cancer cells - Phase 1/2 clinical trial of the HPV-16 E6 TCR is enrolling patients at the National Cancer Institute SANTA MONICA, Calif., Oct. 1, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (NASDAQ:KITE), a clinical-stage ...
Sep 24, 2015
SANTA MONICA, Calif., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced that Marc Better Ph.D., Vice President, Product Sciences, will present during the opening plenary session at IBC Life Sciences' IMMUNO-ONCOLOGY: Advancing the Next Generation of Cancer Immunotherapies Conference, taking place in Alexandri...
Sep 15, 2015
SANTA MONICA, Calif., Sept. 15, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced that Dr. Franz B. Humer, the former Chairman and Chief Executive of Roche Holding Ltd., has been appointed to the Company's Board of Directors. Dr. Humer stated, "Kite Pharma is at the forefront of advancing cancer T cell immunoth...
Sep 14, 2015
SANTA MONICA, Calif., Sept. 14, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced that it has expanded its collaboration with the Netherlands Cancer Institute (NKI). Kite and the NKI have entered into an agreement under which Kite will receive from the NKI the exclusive option to license multiple T cell receptor (TCR) ...
Sep 11, 2015
SANTA MONICA, Calif., Sept. 11, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE) announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending KTE-C19 for designation as an orphan medicinal product for the treatment of PMBCL and MCL. KTE-C19 is an investi...
Sep 3, 2015
Kite SAB Chair Dr. Owen Witte Reappointed to US Cancer PanelProf. Zelig Eshhar Received Israel Prize, the Nation's Highest HonorDr. James Economou Elected to the National Academy of Medicine SANTA MONICA, Calif., Sept. 3, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today commended members of its Scientific Advisory Board (SA...
Sep 3, 2015
SANTA MONICA, Calif., Sept. 3, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE) today announced that the management team will participate in two upcoming investor conferences this month:10th Annual Citi Biotech Conference Date: Thursday, September 10, 2015 Time: 11:00am Eastern Time Location: New York, NYMorgan Stanley Global H...
Aug 17, 2015
Kite KTE-C19 Trial on Track to Advance to Pivotal Phase 2 Kite to Host Conference Call and Webcast on August 17, 2015 at 9:00am Eastern Time SANTA MONICA, Calif., Aug. 17, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today provided an update from the Company's ongoing Phase 1/2 clinical trial of KTE-C19 in patien...
Aug 14, 2015
SANTA MONICA, Calif., Aug. 14, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced that it will host a live conference call on Monday, August 17, 2015, at 9:00am Eastern Time to provide a corporate update. The live webcast and subsequent replay may be accessed by visiting the Company's website at ir.kitepharma.co...
Aug 10, 2015
SANTA MONICA, Calif., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today reported financial results for the quarter ended June 30, 2015. "This past quarter has...
Aug 6, 2015
SANTA MONICA, Calif., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced that management will host a conference call and live webcast discussion at 4:30 p.m. Eastern Time on Monday, August 10, 2015, to discuss financial results for the second quarter ended June 30, 2015, and provide a business update. To access...
Aug 5, 2015
SANTA MONICA, Calif., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced that management will present a company overview at the Canaccord Genuity 35th Annual Growth Conference on August 12, 2015 at 1:30pm Eastern Time. The conference will be held in Boston, MA. The presentation will be available through the Cal...
Jul 1, 2015
SANTA MONICA, Calif. and WHITE PLAINS, N.Y., July 1, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE) and The Leukemia & Lymphoma Society (LLS) announced today that they have entered into a partnership to enhance the development of Kite's lead product candidate, KTE-C19, for the treatment of patients with refractory aggressive non-Hodgkin ...
Jun 22, 2015
Collaboration Combines bluebird bio's Gene Editing and Lentiviral Gene Delivery Technologies and Kite's TCR Capabilities and Exclusive Rights to a TCR Directed Against the HPV-16 E6 Oncoprotein ...
Jun 16, 2015
SANTA MONICA, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), today announced that the Company will host a live webcast in conjunction with its Investor Day on Tuesday, June 23, 2015 at 12:00p.m. ET in New York, NY. The live audio webcast and the accompanying slide presentations can be accessed through the Calend...
Jun 2, 2015
SANTA MONICA, Calif., June 2, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), today announced clinical biomarker data from patients with relapsed/refractory B cell malignancies treated with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in a poster presentation during the 51st Annual Meeting of the American Society of Clinical ...
May 29, 2015
SANTA MONICA, Calif., May 29, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), today announced the Company will report on preliminary biomarker data from patients with relapsed/refractory B cell malignancies treated with anti-CD19 chimeric antigen receptor (CAR) T cell therapy in a poster presentation during the 51st Annual Meeting of the...
May 26, 2015
SANTA MONICA, Calif., May 26, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), today announced that Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer, will present a company overview at the Jefferies 2015 Global Healthcare Conference on June 2, 2015 at 11:00am Eastern Time. The conference will be held in New Yor...
May 21, 2015
SANTA MONICA, Calif., May 21, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), today announced that the first patient in its Phase 1/2 clinical trial of KTE-C19 in patients with refractory aggressive NHL has been treated. KTE-C19 is an investigational therapy in which a patient's T cells are genetically modified to express a CAR designed ...
May 15, 2015
SANTA MONICA, Calif., May 15, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today reported financial results for the quarter ended March 31, 2015. "We're very pleased wi...
May 12, 2015
SANTA MONICA, Calif., May 12, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), today announced that it will release first quarter 2015 financial results on Friday, May 15, 2015. About Kite Pharma Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy produc...
May 4, 2015
SANTA MONICA, Calif., May 4, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), today announced that David D. Chang, M.D., Ph.D., Executive Vice President, Research and Development, and Chief Medical Officer, will present a company overview at three upcoming investor conferences in May 2015: Credit Suisse Antibody Day Wed...
Apr 21, 2015
SANTA MONICA, Calif., April 21, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that Owen Witte, M.D., director of the Eli & Edythe Broad Center of Regenerative Me...
Apr 10, 2015
SANTA MONICA, Calif., April 10, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer, will p...
Apr 6, 2015
SANTA MONICA, Calif., April 6, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced articles being published in the current issue of Science, one article by the Company...
Mar 26, 2015
SANTA MONICA, Calif., March 26, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today reported full-year and fourth quarter 2014 financial results for the period ended December 31...
Mar 25, 2015
SANTA MONICA, Calif., March 25, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products based on chimeric antigen receptor (CAR) and T cell receptor (TCR) gene therapy for the treatment of cancer, today announced that it w...
Mar 17, 2015
- Kite Pharma EU Established as European Headquarters in Amsterdam, Appointing Ton N. M. Schumacher Ph.D. as its Chief Scientific Officer - - Kite to Expand Product Pipeline in TCRs for the Treatment of Solid Tumors, Complementing Kite's Chimeric Antigen Receptor (CAR) Pipeline - SANTA MONICA, Calif., March 17, 2015 (GLOBE NEWSWIRE)...
Mar 6, 2015
SANTA MONICA, Calif., March 6, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that David Chang, M.D., Ph.D., Kite's Executive Vice President, Research and Development, ...
Mar 2, 2015
-Focus on T Cell Response to Tumor-Specific Mutations--Expansion of TCR and CAR Product Pipeline- SANTA MONICA, Calif., Feb. 27, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, toda...
Feb 23, 2015
SANTA MONICA, Calif., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that Arie Belldegrun, M.D., FACS, President and Chief Executive Officer, will present a co...
Feb 19, 2015
SANTA MONICA, Calif., Feb. 19, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that it has entered into a lease agreement for a commercial manufacturing facility in El S...
Feb 3, 2015
SANTA MONICA, Calif., Feb. 3, 2015 /PRNewswire/ -- Kite Pharma, Inc., (Nasdaq: KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced the appointments of Salah D. Kivlighn, Ph.D., as Vice President, Marketing, and Anthony J. Pol...
Feb 2, 2015
SANTA MONICA, Calif., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that Arie Belldegrun, M.D., FACS, Kite's President and Chief Executive Officer, will presen...
Jan 22, 2015
SANTA MONICA, Calif., Jan. 22, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that the Company has expanded its agreement with Tel Aviv Sourasky Medical Center to resea...
Jan 19, 2015
SANTA MONICA, Calif., Jan. 19, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced presentations on the Company's rapid, six-day manufacturing process for the production of ...
Jan 9, 2015
SANTA MONICA, Calif., Jan. 9, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced the appointment of Claudine Prowse, Ph.D., to the newly created position of Senior Vice Pre...
Jan 8, 2015
SANTA MONICA, Calif., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced the appointment of Scott N. Bernstein as Vice President, Intellectual Property Law. Mr. Ber...
Jan 7, 2015
SANTA MONICA, Calif., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that the Company has entered into an exclusive, worldwide license with the National Institut...
Jan 7, 2015
SANTA MONICA, Calif., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that Arie Belldegrun, MD, FACS, President and Chief Executive Officer, will present at the 3...
Jan 6, 2015
SANTA MONICA, Calif., Jan. 6, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that the European Commission (EC), acting on the positive recommendation from the European ...
Jan 5, 2015
THOUSAND OAKS, Calif. and SANTA MONICA, Calif., Jan. 5, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Kite Pharma (NASDAQ:KITE) announced today that the two companies have entered into a strategic research collaboration and license agreement to develop and commercialize the next generation of novel Chimeric Antigen Receptor (CAR) T cell immunotherap...
Dec 30, 2014
SANTA MONICA, Calif., Dec. 30, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that the underwriters of its previously announced follow-on public offering of 3,485,000 s...
Dec 22, 2014
SANTA MONICA, Calif., Dec. 22, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced the Company has submitted an Investigational New Drug (IND) application to the U.S. Food a...
Dec 16, 2014
SANTA MONICA, Calif., Dec. 16, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE),a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, announced today that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq:^NBI...
Dec 10, 2014
SANTA MONICA, Calif., Dec. 10, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced the pricing of its follow-on public offering of 3,485,000 shares of its common stock, an in...
Nov 26, 2014
SANTA MONICA, Calif., Nov. 26, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchang...
Nov 18, 2014
SANTA MONICA, Calif., Nov. 18, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced upcoming oral presentations related to KTE-C19, the Company's most advanced product candid...
Nov 17, 2014
SANTA MONICA, Calif., Nov. 17, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) ha...
Nov 14, 2014
SANTA MONICA, Calif., Nov. 14, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced financial results for the third quarter ended September 30, 2014. "This has been...
Nov 5, 2014
SANTA MONICA, Calif., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that members of the Company's management team will participate in three upcoming conf...
Oct 13, 2014
Phase 1 Clinical Trial Highlights: 14 of 20 pediatric or young adult patients (70%) with relapsed or refractory ALL experienced a complete response. 12 of the 20 patients (60%) achieved a minimal residual disease (MRD)-negative complete response. 10 of the patients who had an MRD-negative complete response subseque...
Oct 3, 2014
SANTA MONICA, Calif., Oct. 3, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that David Chang, M.D., Ph.D., Kite Pharma's Executive Vice President, Research and D...
Sep 16, 2014
SANTA MONICA, Calif., Sept. 16, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that Arie Belldegrun, M.D., FACS, President and Chief Executive Officer, will provi...
Aug 26, 2014
SANTA MONICA, Calif., Aug. 26, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced its participation at Citi's 9th Annual Biotech Conference at the Mandarin Oriental i...
Aug 25, 2014
Phase 1-2a Clinical Trial Highlights:12 of 13 Total Evaluable Patients with Advanced B Cell Malignancies Had Complete Remissions (8 Patients) or Partial Remissions (4 Patients) Resulting in a 92% Objective Response Rate4 of 7 Evaluable Patients with Chemotherapy-Refractory Diffuse Large B-cell Lymphoma (DLBCL) Achieved Complete Remissions, 3 of Whi...
Aug 14, 2014
Successfully Completed Initial Public Offering, Raised Net Proceeds of $134.1 MillionKite Advancing Clinical Development Pipeline of Its Proprietary eACT™-Based Product Candidates SANTA MONICA, Calif., Aug. 14, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing...
Jun 23, 2014
SANTA MONICA, Calif., June 23, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that the underwriters of its previously announced initial public offering have exercised in...
Jun 20, 2014
SANTA MONICA, Calif., June 20, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq: KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced the pricing of its initial public offering of 7,500,000 shares of its common stock at a pr...
Jun 10, 2014
Santa Monica, CA – June 10, 2014 – Kite Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced the expansion of Kite's research and development leadership team with the appointments of William Y. Go, M...
Jun 6, 2014
Santa Monica, CA – June 6, 2014 – Kite Pharma, Inc., a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT™) products for cancer, today announced that it has entered into an exclusive, worldwide license with the National Institutes of Health (NIH) to certain intellectual propert...
Jun 2, 2014
Santa Monica, CA – June 2, 2014 – Kite Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced the appointment of David D. Chang, M.D., Ph.D., as Executive Vice President, Research and Development, and C...
May 30, 2014
Santa Monica, CA – May 30, 2014 – Kite Pharma, Inc. (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced the Company will provide details on key features of the rapid, 6-day manufacturing process that is ex...
May 19, 2014
Santa Monica, CA – May 19, 2014 – Kite Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC...
May 12, 2014
Santa Monica, CA – May 12, 2014 – Kite Pharma, Inc. (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced the appointment of Jeffrey S. Wiezorek, M.D., M.S., to the newly created position of Vice President, ...
Apr 29, 2014
Santa Monica, CA – April 28, 2014 – Kite Pharma, Inc. (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced the completion of a $50 million mezzanine private financing of convertible notes.  Participan...
Apr 14, 2014
Santa Monica, CA – April 14, 2014 – Kite Pharma, Inc. (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that Ms. Cynthia M. Butitta has been appointed its Chief Operating Officer in addition to serving i...
Apr 11, 2014
Santa Monica, CA – April 11, 2014 – Kite Pharma, Inc. (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced the appointment of Jonathan M. Peacock, former Chief Financial Officer of Amgen, to the Company's B...
Apr 2, 2014
Santa Monica, CA – April 2, 2014 – Kite Pharma, Inc. (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for cancer, today announced the appointment of Arie Belldegrun, M.D., FACS, as President and Chief Executive Officer.  Dr. Belldegrun, who ...
Mar 31, 2014
Los Angeles, CA – March 31, 2014 – Kite Pharma, Inc. (Kite), a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT™) products for cancer, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation f...
Jan 17, 2014
LOS ANGELES, Jan. 17, 2014 -- Kite Pharma, Inc. (Kite), a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT™) products for cancer, today announced the appointment of Rizwana F. Sproule, Ph.D., to...
Jan 9, 2014
New York, Jan. 9, 2014 -- NeoStem, Inc. (NASDAQ:NBS) and its subsidiary, Progenitor Cell Therapy, LLC (“PCT”), announced today the execution of a Services Agreement with Kite Pharma, Inc., under which PCT will provide cell therapy process development and manufacturing services for Kite Pharma’s lead engineered Autologous T...
Jan 8, 2014
Los Angeles, CA – January 8, 2014 – Kite Pharma Inc. (Kite), a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT™) products for cancer, today announced the appointment of Cynthia M. Butitta to the newly created position of Executive Vice President and Chief Financial Offic...
Dec 7, 2013
At the 2013 American Society of Hematology meeting in Dec. 2013, James Kochenderfer, M.D., investigator in the Experimental Transplantation and Immunology Branch, NCI, presented findings from two clinical trials evaluating the use of genetically modified immune system T cells as cancer therapy.  These studies were performed in close co...
Dec 7, 2013
Los Angeles, CA – December 7, 2013 – Kite Pharma, Inc. (Kite), today announced that Dr. Arie Belldegrun, Executive Chairman and Founder of Kite Pharma, will present at the 32nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2014, at 1:30 p.m. Pacific Time.  The conference will be held at the We...
Dec 7, 2013
LOS ANGELES, CA (December 7, 2013) -- Kite Pharma, Inc. (Kite), a clinical-stage biotechnology company focused on engineered autologous T cell therapy (eACT) products for cancer, today announced positive clinical data demonstrating that Kite’s most advanced product candidate can produce robust and ...
Aug 8, 2013
Los Angeles, CA - August 8, 2013 - Kite Pharma Inc. (Kite), a clinical stage biotechnology company focused on developing engineered autologous T cell therapy (eACT) products for cancer, today announced the appointment of three leading experts in the areas of immunotherapy, chimeric antigen receptor (CAR) te...
May 30, 2013
Los Angeles, CA (May 30, 2013) -- Kite Pharma Inc. (Kite), a clinical stage biotechnology company focused on developing engineered autologous T cell therapy (eACT) products for cancer, today announced the appointment of Keith Nolop, M.D. as Chief Medical Officer. Dr. Nolop, who brings to Kite over 20 years of successful drug development experien...
May 15, 2013
Los Angeles, CA (May 15, 2013) -- Kite Pharma Inc. (Kite), a clinical stage biotechnology company focused on developing innovative targeted immunotherapies for cancer, today announced that it has closed a $20 million private placement of shares of its Series A Preferred Stock. In addition to the $20 million in new funds, Kite converted $15 milli...
Oct 16, 2012
Los Angeles, CA, October 16, 2012--- Kite Pharma Inc. (Kite), a biotechnology company focused on developing innovative targeted immunotherapies for cancer, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer In...
Jul 11, 2011
LOS ANGELES - July 11, 2011 - Kite Pharma, Inc., a biopharmaceutical company focused on developing innovative active immunotherapies for cancer, announced today the appointment of Adrian Bot, M.D., Ph.D., as Chief Scientific Officer. Dr. Bot brings over 13 years of experience in the biopharmaceutical industry and expertise in discovery, research...
Mar 9, 2011
Los Angeles, CA, March 9, 2011 – Kite Pharma, Inc., a biopharmaceutical company focused on developing innovative active immunotherapies for cancer, today announced that it has raised $15 million in an initial round of financing through a private placement with a syndicate of venture and qualified investors. Riverbank Capital Inc., a FINRA...
Sep 20, 2010
LOS ANGELES, Calif., September 20, 2010 – Kite Pharma, Inc., a biopharmaceutical company focused on developing innovative active immunotherapies for cancer, announced today the appointment of Gloria Lee, M.D., Ph.D., as Chief Medical Officer. Dr. Lee, who brings over 18 years of oncology clinical development...
Sep 16, 2010
LOS ANGELES, Calif., September 16, 2010 – Kite Pharma, Inc., a biopharmaceutical company, focused on developing innovative active immunotherapies for cancer, announced today the appointment of Aya Jakobovits, Ph.D. as President and Chief Executive Officer.  Dr. Jakobovits brings over 20 years of broad experience in the biotech in...
Page:
...
Next Last
 
= add release to Briefcase